The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
“Epigenetic clocks have been a major advance for the aging field, as they enable the precise study of biological aging without requiring a protracted timeline,” said Elysium Health chief scientist and MIT professor Leonard Guarente, Ph.D.
Hagit Kamin, CEO of SyqeAir Medical, said: It is our privilege to help veterans who mainly suffer from chronic pain and PTSD to establish a functioning daily routine for themselves, and we are honored for the opportunity to make a positive impact on their lives.
tDCS devices aren’t a replacement for mental health professionals or pharmaceuticals. Still, they’re medically-approved devices (in most instances) that can alleviate symptoms of depression and allow many to cope on a day-to-day basis.
“Achieving MDR certification is another major milestone for Eyenuk and a result of our early adaptation to the more stringent requirements of the new regulation,” said Kaushal Solanki, Chief Executive Officer and Founder of Eyenuk. “Moreover, this certification expanding our ability to market the EyeArt platform for two additional disease conditions in the EU reflects the flexibility of our AI-based platform and the depth of the clinical research conducted across the globe validating its effectiveness.”
“We’re very excited about our revolutionary solution for age related macular degeneration (AMD), accommodative vision correction and the long-term prevention of blindness. According to recent estimates, close to 200 million people globally are affected by AMD which is expected to grow to 288 million people by 2040. CEYEBER will have a profound impact on the quality of life and vision for millions of people worldwide,” explained Robert Edward Grant, Founder and CEO of CEYEBER.
The Vivistim Paired VNS System is an FDA Breakthrough Device that was granted pre-market authorization (PMA) approval on August 27, 2021. Unlike other neurostimulation technologies, the Vivistim System is used in conjunction with rehabilitation therapy to help ischemic stroke survivors who have chronic arm and hand deficits improve their upper limb function.